MLYS Stock Analysis: Buy, Sell, or Hold?
MLYS - Mineralys Therapeutics, Inc. Common Stock
$25.52
-0.67 (-2.56%)
▼
5d:
-4.46%
30d:
-5.09%
90d:
-4.24%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
8d
Smart Money Accumulation
None View Scanner →
Strength: 6.2/10
Get Alerted When MLYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MLYS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: MLYS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: MLYS is currently trading at $25.52, which is considered oversold relative to its 30-day fair value range of $26.16 to $28.52.
Technical Outlook: Technically, MLYS is showing sideways momentum. The price is currently testing key support at $25.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $49.00 (+92.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MLYS is showing sideways momentum. The price is currently testing key support at $25.20. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $49.00 (+92.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$26.16 -
$28.52
Company Quality Score
52/100
(HOLD)
Options IV Signal
3th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 3th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 92.0% below Wall St target ($49.00)
Trading Range Analysis
30-Day Trading Range
$26.16 -
$28.52
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.54
(9.9%)
Support & Resistance Levels
Support Level
$25.20
Resistance Level
$28.19
Current Trend
Sideways
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.17
Wall Street Target
$49.00
(+92.0%)
Share & Embed Analysis
Last updated: August 02, 2026 6:26 PM ET
Data refreshes hourly during market hours. Next update: 7:26 PM
Data refreshes hourly during market hours. Next update: 7:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MLYS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
David Malcom Rodman
SELL
416 shares
2026-04-17
David Malcom Rodman
SELL
6348 shares
2026-04-15
David Malcom Rodman
SELL
14058 shares
2026-04-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
Advanced MLYS Option Strategies
Professional options setups generated by AI based on today's MLYS price and gamma walls.
